Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort) (3C)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01766596|
Recruitment Status : Active, not recruiting
First Posted : January 11, 2013
Last Update Posted : September 1, 2016
The aim of the study proposed in Dijon is above all to focus on the possible relationship between age-related ocular pathologies (AMD and glaucoma) and et les degenerative neurological and cardiac pathologies.
The principal objective is to seek in subjects who have undergone cerebral MRI and echocardiography, associations between the thickness of postganglionic fibers measured by Optical Coherence Tomography at the 7th year (n=1500) and signs of cerebral impairment (psycho-cognitive tests, circulation time, MRI signs). This association will be studied after taking into account the principal environmental (particularly dietary) and genetic risk factors.
|Condition or disease||Intervention/treatment|
|AMD Glaucoma||Procedure: Optical Coherence Tomography|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||3000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort): Seek Correlations Between Signs of Neurological and Vascular Degeneration and Signs of Ocular Aging|
|Study Start Date :||October 2009|
|Primary Completion Date :||October 2013|
|3C cohort||Procedure: Optical Coherence Tomography|
- Measure the mean thickness of postganglionic fibers [ Time Frame: T=7 years of the 3C cohort ]Measure the thickness of postganglionic fibers by Optical Coherence Tomography in the 4 quadrants of the peripapillary sclera.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01766596
|Dijon, France, 21000|